Top

Journal of Cancer Research and Clinical Oncology

Published in:

22-09-2023 | Hepatocellular Carcinoma | Research

Construction of an anoikis‒related prognostic signature to predict immunotherapeutic response and prognosis in hepatocellular carcinoma

Authors: Chen Xiong, Guoqiang Pan, Hanchao Wang, Guangxiao Meng, Lunjie Yan, Ruizhe Li, Yuchuan Yan, Yafei Yang, Xiao Zhang, Chuncheng Yang, Zhaoru Dong, Tao Li

Published in: Journal of Cancer Research and Clinical Oncology | Issue 18/2023

Abstract

Purpose

Anoikis resistance is an important inducer of tumor metastasis. The role of anoikis-related genes (ARGs) in hepatocellular carcinoma (HCC) remains unclear.

Methods

A list of ARGs was obtained and regression analysis was employed to assemble an anoikis-related prognostic signature and risk score formula from mRNA data and clinical prognostic data downloaded from The Cancer Genome Atlas database. Quantitative real-time PCR (qRT-PCR) was performed on clinical samples to validate the selected ARGs expressions. Kaplan‒Meier curves, ROC curves, and Cox regression analyses were used to demonstrated the prognostic value of this signature. Biological functional enrichment analysis and immune infiltration analysis were utilized to analyze the differences in potential biological functions, immune cell infiltration, immune functions, and immunotherapeutic responses.

Results

A prognostic signature based on 6 ARGs and corresponding prognostic nomogram were established. Our qRT-PCR results showed a higher expression of 6 ARGs in HCC tissues (p value < 0.05). Kaplan‒Meier curves, ROC curves, and Cox regression analyses demonstrated good prognostic value of the signature in HCC (p value < 0.05). Significant differences between the enriched biological functions and immune landscapes of patients in different risk groups were discovered (p value < 0.05). In addition, patients with higher risk scores possibly had poor therapeutic response to transhepatic arterial chemotherapy and embolization or sorafenib, but their responses to immunotherapy might be more effective.

Conclusion

A successful anoikis-related prognostic signature and corresponding clinical nomogram were established, which might facilitate better predictions of prognosis and therapeutic responses for HCC patients.

Available only for authorised users

Barrett T, Wilhite SE, Ledoux P et al (2013) NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res 41:D991-995 PubMed

Chen Z, Liu X, Zhu Z et al (2022) A novel anoikis-related prognostic signature associated with prognosis and immune infiltration landscape in clear cell renal cell carcinoma. Front Genet 13:1039465 PubMedPubMedCentral

Chuah S, Lee J, Song Y et al (2022) Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma. J Hepatol 77:683–694 PubMed

Corpuz AD, Ramos JW, Matter ML (2020) PTRH2: an adhesion regulated molecular switch at the nexus of life, death, and differentiation. Cell Death Discov 6:124 PubMedPubMedCentral

Dennis G Jr, Sherman BT, Hosack DA et al (2003) DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 4:P3 PubMed

Gao R, Kalathur RKR, Coto-Llerena M et al (2021) YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol Med 13:e14351 PubMedPubMedCentral

Gilmore AP (2005) Anoikis. Cell Death Differ 12(Suppl 2):1473–1477 PubMed

Hausmann M, Leucht K, Ploner C et al (2011) BCL-2 modifying factor (BMF) is a central regulator of anoikis in human intestinal epithelial cells. J Biol Chem 286:26533–26540 PubMedPubMedCentral

Hudson TJ, Anderson W, Artez A et al (2010) International network of cancer genome projects. Nature 464:993–998 PubMed

Khotskaya YB, Beck BH, Hurst DR et al (2014) Expression of metastasis suppressor BRMS1 in breast cancer cells results in a marked delay in cellular adhesion to matrix. Mol Carcinog 53:1011–1026 PubMed

Li T, Fan J, Wang B et al (2017) TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Can Res 77:e108–e110

Li K, Zhao G, Ao J et al (2019) ZNF32 induces anoikis resistance through maintaining redox homeostasis and activating Src/FAK signaling in hepatocellular carcinoma. Cancer Lett 442:271–278 PubMed

Lin Z, Niu Y, Wan A et al (2020) RNA m(6) A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J 39:e103181 PubMedPubMedCentral

Llovet JM, Castet F, Heikenwalder M et al (2022) Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 19:151–172 PubMed

Martin SP, Fako V, Dang H et al (2020) PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma. J Exp Clin Cancer Res CR 39:99 PubMed

Mo CF, Li J, Yang SX et al (2020) IQGAP1 promotes anoikis resistance and metastasis through Rac1-dependent ROS accumulation and activation of Src/FAK signalling in hepatocellular carcinoma. Br J Cancer 123:1154–1163 PubMedPubMedCentral

Qi X, Guo J, Chen G et al (2022) Cuproptosis-related signature predicts the prognosis, tumor microenvironment, and drug sensitivity of hepatocellular carcinoma. J Immunol Res 2022:3393027 PubMedPubMedCentral

Qiao L, Zhang Q, Sun Z et al (2021) The E2F1/USP11 positive feedback loop promotes hepatocellular carcinoma metastasis and inhibits autophagy by activating ERK/mTOR pathway. Cancer Lett 514:63–78 PubMed

Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T (2019) Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev 72:28–36 PubMed

Sangro B, Sarobe P, Hervás-Stubbs S, Melero I (2021) Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 18:525–543 PubMedPubMedCentral

Shi Y, Shang J, Li Y et al (2022) ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinoma. Cancer Med 12(3):3786–3796 PubMedPubMedCentral

Song J, Liu Y, Liu F et al (2021) The 14-3-3σ protein promotes HCC anoikis resistance by inhibiting EGFR degradation and thereby activating the EGFR-dependent ERK1/2 signaling pathway. Theranostics 11:996–1015 PubMedPubMedCentral

Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 71:209–249 PubMed

Taddei ML, Giannoni E, Fiaschi T, Chiarugi P (2012) Anoikis: an emerging hallmark in health and diseases. J Pathol 226:380–393 PubMed

Tang W, Chen Z, Zhang W et al (2020) The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther 5:87 PubMedPubMedCentral

Tomczak K, Czerwińska P, Wiznerowicz M (2015) The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Poznan, Poland) 19:A68-77

Villanueva A (2019) Hepatocellular carcinoma. N Engl J Med 380:1450–1462 PubMed

Wang YN, Zeng ZL, Lu J et al (2018) CPT1A-mediated fatty acid oxidation promotes colorectal cancer cell metastasis by inhibiting anoikis. Oncogene 37:6025–6040 PubMed

Wei X, Zhao L, Ren R et al (2021) MiR-125b loss activated HIF1α/pAKT loop, leading to transarterial chemoembolization resistance in hepatocellular carcinoma. Hepatology (baltimore, MD) 73:1381–1398 PubMed

Whelan KA, Caldwell SA, Shahriari KS et al (2010) Hypoxia suppression of Bim and Bmf blocks anoikis and luminal clearing during mammary morphogenesis. Mol Biol Cell 21:3829–3837 PubMedPubMedCentral

Wu FQ, Fang T, Yu LX et al (2016) ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α. J Hepatol 65:314–324 PubMed

Xia S, Pan Y, Liang Y, Xu J, Cai X (2020) The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine 51:102610 PubMedPubMedCentral

Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR (2019) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16:589–604 PubMedPubMedCentral

Yu M, Lu B, Liu Y, Me Y, Wang L, Li H (2017) Interference with Tim-3 protein expression attenuates the invasion of clear cell renal cell carcinoma and aggravates anoikis. Mol Med Rep 15:1103–1108 PubMedPubMedCentral

Yu Y, Zhao D, Li K et al (2020) E2F1 mediated DDX11 transcriptional activation promotes hepatocellular carcinoma progression through PI3K/AKT/mTOR pathway. Cell Death Dis 11:273 PubMedPubMedCentral

Yu Y, Song Y, Cheng L et al (2022) CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells. J Exp Clin Cancer Res CR 41:188 PubMed

Zhang YF, Zhang AR, Zhang BC et al (2013) MiR-26a regulates cell cycle and anoikis of human esophageal adenocarcinoma cells through Rb1-E2F1 signaling pathway. Mol Biol Rep 40:1711–1720 PubMed

Zhang X, Cheng SL, Bian K et al (2015) MicroRNA-26a promotes anoikis in human hepatocellular carcinoma cells by targeting alpha5 integrin. Oncotarget 6:2277–2289 PubMed

Zhang YY, Li XW, Li XD et al (2022a) Comprehensive analysis of anoikis-related long non-coding RNA immune infiltration in patients with bladder cancer and immunotherapy. Front Immunol 13:1055304 PubMedPubMedCentral

Zhang H, Huang Y, Yang E et al (2022b) Identification of a fibroblast-related prognostic model in glioma based on bioinformatics methods. Biomolecules 12:1598 PubMedPubMedCentral

Zhou C, Zhang Z, Zhu X et al (2020) N6-Methyladenosine modification of the TRIM7 positively regulates tumorigenesis and chemoresistance in osteosarcoma through ubiquitination of BRMS1. EBioMedicine 59:102955 PubMedPubMedCentral

Title: Construction of an anoikis‒related prognostic signature to predict immunotherapeutic response and prognosis in hepatocellular carcinoma
Authors: Chen Xiong
Guoqiang Pan
Hanchao Wang
Guangxiao Meng
Lunjie Yan
Ruizhe Li
Yuchuan Yan
Yafei Yang
Xiao Zhang
Chuncheng Yang
Zhaoru Dong
Tao Li
Publication date: 22-09-2023
Publisher: Springer Berlin Heidelberg
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Sorafenib
Published in: Journal of Cancer Research and Clinical Oncology / Issue 18/2023
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-05428-0

Webinar | 08-11-2023 | 18:00 (CET)

Keynote Webinar | Spotlight on Diet and Diabetes

Watch now

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. Highlights include discussion of the recent EASD guidelines, therapeutic diets, food types and processing, plus psychological factors that influence patient success, and the drivers of healthy eating and diabetes control.

Prof. Mike Lean

Prof. Falko Sniehotta

Keynote Webinar | Spotlight on Diet and Diabetes

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 18/2023

Real-world treatment outcomes of carfilzomib plus dexamethasone in patients with relapsed and/or refractory multiple myeloma, focusing on the impact of trial-fitness: CAtholic REsearch network for Multiple Myeloma study (CAREMM-2203)

Current status and frontier tracking of clinical trials on Metformin for cancer treatment

Identification of a TRP channel-related risk model for predicting prognosis and therapeutic effects of patients with hepatocellular carcinoma

CPVL suppresses metastasis of nasopharyngeal carcinoma through inhibiting epithelial–mesenchymal transition

B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy

MicroRNA biomarkers and their use in evaluating the prognosis of lung cancer

Keynote Webinar | Spotlight on Diet and Diabetes